TITLE

POSITIVE RESULTS FROM PHASE 1B OF OXYCODONE PATCH

PUB. DATE
March 2010
SOURCE
Worldwide Biotech;Mar2010, Vol. 22 Issue 3, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the positive results of the Phase 1B clinical study conducted by Phosphagenics Ltd. using its Targeted Penetration Matrix (TPMâ„¢) for the transdermal delivery of oxycodone. The trial has successfully demonstrated that daily application of a TPMâ„¢-oxycodone patch delivered therapeutic bloodstream levels of oxycodone that is reproducible and consistent. The study also showed that oxycodone plasma concentration increased throughout the dosing period after application of the matrix patch on a daily basis.
ACCESSION #
48366829

 

Related Articles

  • Phosphagenics working on topical opioid patch.  // Australian Life Scientist;Mar/Apr2013, Vol. 10 Issue 2, p6 

    The article informs that Phosphagenics Ltd. has included an oxycodone-based patch designed for local pain relief in its pain patch portfolio and is also planning to start clinical trials of a similar version of the patch in the third quarter.

  • Monetising a platform technology. Ogru, Esra // Australasian Biotechnology;Oct2011, Vol. 21 Issue 3, p30 

    This sector is acutely aware of the squeeze on Australian companies in raising ongoing capital. Phosphagenics is implementing a range of strategies to reduce the need to return to the market for capital. Phosphagenics' primary goal is to develop a transdermal oxycodone patch. A successfully...

  • R&D Update.  // PharmaWatch: CNS;Nov2007, Vol. 6 Issue 11, p10 

    The article offers news briefs related to pharmaceutical industry worldwide in 2007. Adlea is a long-acting, non-opiate analgesic drug which designed for weeks to months pain relief in single local dose during the surgical procedure. Australian company Phosphagenics has received approval to...

  • CLINICAL TRIALS NEWS.  // Applied Clinical Trials;Jun2007, Vol. 16 Issue 6, p30 

    The article offers news briefs related to clinical trials. Paris, France-based NicOx SA has begun its second Phase III naproxcinod trial to verify the effectiveness of the drug. Sydney, New South Wales-based Alchemia Lid. has completed its Phase II study comparing its product HyCAMP with...

  • TPM/OXYCODONE PATCH TRIAL RECEIVES ETHICS APPROVAL.  // Biotech Business;Jan2015, Vol. 28 Issue 1, p2 

    The article reports that biotechnology company Phosphagenics Ltd. has earned ethics approval for the commencement of proof of concept Phase 2 trial in Australia for its TPM/Oxycodone patch. Topics discussed include the trial's goal of determining the effectiveness of the patch for lessening the...

  • Plasma and Urine Dimercaptopropanesulfonate Concentrations after Dermal Application of Transdermal DMPS (TD-DMPS) Cohen, Jennifer P.; Ruha, Anne-Michelle; Curry, Steven C.; Biswas, Kallol; Westenberger, Benjamin; Ye, Wei; Caldwell, Kathleen L.; LoVecchio, Frank; Burkhart, Keith; Samia, Nasr // Journal of Medical Toxicology;Mar2013, Vol. 9 Issue 1, p9 

    2,3-Dimercaptopropane-1-sulfonate (DMPS) is a metal chelator approved in Europe for oral or intravenous use for heavy metal poisoning. Transdermally applied DMPS (TD-DMPS) is used by some alternative practitioners to treat autism, despite the absence of evidence for its efficacy. We found no...

  • Formulation And Evaluation Of Controlled Release Transdermal Patches Of Theophylline - Salbutamol Sulphate. Murthy, Narasimha S; Hiremath, Shobha Rani R // Internet Journal of Asthma, Allergy & Immunology;2002, Vol. 2 Issue 1, p33 

    Transdermal formulations containing theophylline and salbutamol sulphate were formulated using hydroxy propyl methyl cellulose. Theophylline was loaded by adsorption with the aid of co-adsorbate, sodium chloride. The formulations were subjected to in vitro release studies and the dose of...

  • Transdermal Delivery of Antihypertensive Agents: A tabular update. Jain, Ashish; Mishra, Anurag; Nayak, Satish; Soni, Vandana // International Journal of Drug Delivery;Apr2011, p1 

    Transdermal Drug Delivery System is viable drug delivery platform technology and has a strong market world wide. Transdermal Drug Delivery System is particularly desirable for drugs that need prolonged administration at controlled plasma level that basis make appropriateness to antihypertensive...

  • Targeting Plasma Glucose: Preprandial Versus Postprandial. Schrot, Richard J. // Clinical Diabetes;Fall2004, Vol. 22 Issue 4, p169 

    Discusses the role of plasma glucose in clinical studies on diabetes control. Physiology of normal and abnormal glucose; Information on mean plasma glucose; Discussion on postprandial glucose.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics